지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
이용수
초록· 키워드
오류제보하기
Purpose: The aim of this study was to compare retrospectively the efficacy of anti-osteoporotic agents (RAL-Raloxifene60 mg, ALD-weekly alendronate 70 mg, RSD-weekly risedronate 35 mg, AVD3-weekly alendronate 70 mg/vitaminD3 2800IU, IBD-quarterly IV ibandronate 3 mg/3 ml, ZLD-yearly IV zoledronate 5 mg/100 ml) in postmenopausalpatients with osteoporosis or osteopenia. Method: This study retrospectively reviewed medical record and compared thelumbar spine BMD percentage changes of each medicine group one year later from the baseline. 209 patients (27, 50,60, 30, 35, and 7 patients in RAL, ALD, RSD, AVD3, IBD, and ZLD groups, respectively) are within the inclusion criteriafor the study. Results: From baseline to month 12, lumbar spine BMD increased significantly larger with bisphosphonategroups, compared to SERM (p < 0.05). In all bisphosphonate groups, the lumbar spine BMD were increasedsignificantly from baseline. Of the bisphosphonates, the changes from baseline in BMD of IV bisphosphonates weremore larger than those of oral bisphosphonates, and yearly, quarterly bisphosphonates yielded significantly greater BMDgains, compared with weekly bisphosphonate groups (p < 0.05). In addition, patients receiving 70 mg weekly alendronate+vitamin D3 had greater gains in BMD than alendronate Single preparation (p < 0.05). Conclusion: Bisphosphonatesyielded significantly greater BMD gains than SERM. Of the bisphosphonates, the changes from baseline in BMDof yearly, quarterly IV bisphosphonates yielded significantly greater BMD gains, compared with weekly oral bisphosphonategroups. In addition, vitamin D3 plays an significant role in BMD gains.
목차
등록된 정보가 없습니다.
참고문헌 (22)
참고문헌 신청
NIH Consensus Panel on Osteoporosis Prevention, Diagnosis, and Therapy. / 2001 / Osteoporosis prevention, diagnosis, and therapy / JAMA 285:785~795
Vestergaard P. / 2005 / Anti-resorptive therapy for the prevention of postmenopausal osteoporosis : when should treatment begin? / Treat Endocrinol 4(5):263~277
Tosteson AN. / 2008 / Therapies for Treatment of Osteoporosis in US Women : Cost-effectiveness and Budget Impact Considerations / Am J Manag Care 14(9):605~615
2007 / Physician's Guideline for Osteoporosis / Korean Society for Bone and Mineral Research
Rakel / 2008 / Conn's Current Therapy 2008, 60th ed :149
Vestergaard P. / 2005 / Anti-resorptive therapy for the prevention of postmenopausal osteoporosis : when should treatment begin? / Treat Endocrinol 4(5):263~277
Tosteson AN. / 2008 / Therapies for Treatment of Osteoporosis in US Women : Cost-effectiveness and Budget Impact Considerations / Am J Manag Care 14(9):605~615
2007 / Physician's Guideline for Osteoporosis / Korean Society for Bone and Mineral Research
Rakel / 2008 / Conn's Current Therapy 2008, 60th ed :149
이 논문의 저자 정보
최근 본 자료
댓글(0)
0